However, the data show that this is true for its inhibition of VEGFR2, a target of angiogenic drugs, but not for PDGFRα, a target in gastro-intestinal stromal tumours, an indication for which regorafenib is approved as well (Table 1). This evidence concerns the gene KDR and gastrointestinal stromal tumor.